252233-33-3

Upstream product

• 60532-50-5 5-chloro-2,4-dinitrobenzamide 
• 140-75-0 para-fluorobenzylamine 
• 535-80-8 3-chlorobenzoate 
• 50425-06-4 5-chloro-2,4-dinitrobenzoyl chloride 
• 136833-36-8 5-chloro-2,4-dinitrobenzoic acid 

Downstream Products

• 252232-76-1 3-[1-[(4-Fluorophenyl)methyl]-7,8-dihydro-8-oxo-1H-imidazo[4,5-g]-quinazolin-6-yl]-4-propoxybenzoic acid 
• 252232-75-0 1-(4-fluorophenylmethyl)-6-(4-cyano-2-propoxyphenyl)-1H-imidazo[4,5-g]quinazolin-8(7H)-one 
• 252232-74-9 6-(5-bromo-2-propoxy-phenyl)-1-(4-fluoro-benzyl)-1,7-dihydro-imidazo[4,5-g]quinazolin-8-one 
• 252233-45-7 5-amino-1-[(4-fluorophenylmethyl)amino]-1H-benzimidazole-6-carboxamide 

Relevant academic research and scientific papers

Quinazolinone inhibitors of cGMP phosphodiesterase

Novel quinazolinone compounds, methods of using such compounds in the treatment of cGMP-associated conditions such as erectile dysfunction, and pharmaceutical compositions containing such compounds.

N-3-substituted imidazoquinazolinones: Potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction

Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity relative to sildenafil may result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE-associated adverse effects. This paper describe